Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.33 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16132316 | 0.88 | SMN1; SMN2 (0.59) | SMN1; SMN2L3MBTL1CYP3A4CYP17A1AHR | |
| SCHEMBL20148780 | 0.81 | KCNA5 (0.50) | SMN1; SMN2L3MBTL1CYP19A1CYP3A4CYP17A1 | |
| SCHEMBL20148779 | 0.80 | SMN1; SMN2 (0.53) | SMN1; SMN2L3MBTL1CYP3A4CYP17A1AHR | |
| SCHEMBL16132367 | 0.78 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL1CYP3A4CYP17A1AHR | |
| SCHEMBL20362732 | 0.78 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL1CYP19A1AHRCHRM3 | |
| SCHEMBL16231358 | 0.78 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL1CYP19A1AHRCHRM3 | |
| SCHEMBL20148793 | 0.77 | SMN1; SMN2 (0.47) | SMN1; SMN2L3MBTL1CYP3A4CYP17A1AHR | |
| SCHEMBL16132423 | 0.76 | SMN1; SMN2 (0.46) | SMN1; SMN2L3MBTL1CYP3A4CYP17A1AHR | |
| SCHEMBL16230705 | 0.75 | CYP19A1 (0.49) | SMN1; SMN2L3MBTL1CYP19A1AHRCHRM3 | |
| SCHEMBL21308429 | 0.74 | SMN1; SMN2 (0.45) | SMN1; SMN2L3MBTL1CYP19A1AHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133212-A1 | COMBINATION OF A BCL-2 INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER | GILEAD SCIENCES, INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133212-A1 | COMBINATION OF A BCL-2 INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER | BCL2, BAK1, BRD4 | SMN1; SMN2 3797/4885L3MBTL1 1270/4885CYP19A1 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.